Legal & Disputes
Robbins LLP Announces EyePoint Class Action Covering May 2025 to August 2026 Purchases
By News Desk ·
Key takeaways
- Robbins LLP informed investors of a class action against EyePoint covering purchases from May 27, 2025 through August 14, 2026.
- The complaint alleges EyePoint overstated DURAVYU's efficacy for wet age-related macular degeneration.
- EyePoint shares fell 66.98% on August 17, 2026 and 85.28% on October 19, 2026, when the company also cut its workforce by 53%.
Robbins LLP informed investors of a class action filed against EyePoint, Inc. on behalf of purchasers of its securities between May 27, 2025 and August 14, 2026, both dates inclusive. The shareholder rights firm announced the case in a Business Wire release. The complaint alleges EyePoint misled investors about the efficacy and viability of DURAVYU for wet age-related macular degeneration.
What the EyePoint Complaint Alleges
According to the complaint, EyePoint was evaluating DURAVYU in its Phase 3 LUGANO and LUCIA trials, both of which measured average change in best corrected visual acuity at weeks 52 and 56 versus baseline. The plaintiff alleges the company promoted DURAVYU's "differentiated profile," a "uniquely suited" mechanism of action and a "robust" and "best-in-class" efficacy profile based on data from other studies. The complaint contends EyePoint did not disclose that DURAVYU was less effective than investors had been led to believe, overstating its clinical, regulatory and commercial prospects.
EyePoint develops and commercializes therapeutics for patients with serious retinal diseases. EyePoint Pharmaceuticals reported at the UBS biopharma conference that DURAVYU failed the primary non-inferiority endpoint in two wet AMD Phase III trials while showing strong secondary data on fluid control and safety, Investing.com reported.
Robbins' Record and the EyePoint Case
Robbins LLP is a San Diego firm founded in 2002 that represents shareholders, institutional investors, whistleblowers and consumers in securities fraud, shareholder derivative, antitrust and consumer class actions on a contingency fee basis, according to akta.pro company records. The same records put its headcount at 11 to 50 and describe a whistleblower practice spanning the False Claims Act qui tam and the SEC, CFTC and IRS whistleblower programs. The firm says it has helped shareholders recover more than $1 billion of value through litigation, settlements and corporate governance reforms.
"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.
Earlier Robbins Investor Alerts
Robbins LLP issued a series of investor alerts in the weeks before the EyePoint notice. On November 12, 2026, the firm informed investors of a class action against NuScale Power Corporation covering purchases from February 27 to September 10, 2026, FinancialContent Business Page reported. That same day, it announced a securities fraud class action against Portillo's Inc. in which the stock fell 31.2% to $3.93 per share after partial disclosures, FinancialContent Business Page reported. On November 10, 2026, Robbins informed investors of a class action against CVRx, Inc. alleging False Claims Act and Anti-Kickback Statute violations, FinancialContent Business Page reported.
EyePoint's Trial Results and Next Steps
The complaint states that EyePoint's stock fell $9.88 per share, or 66.98%, to close at $4.87 on August 17, 2026, after the LUGANO topline release said the primary endpoint versus 2 mg aflibercept on-label control was not achieved in the full dataset. On October 19, 2026, the stock fell $2.55 per share, or 85.28%, to close at $0.44 after disappointing LUCIA results and the company's announcement that it was terminating its late-stage wet AMD program and reducing its workforce by 53%. Investors in the class period may seek appointment as lead plaintiff; those who do not seek appointment may remain absent class members.